Singapore working on securing portfolio of Covid-19 vaccines: Minister

Negotiations with various pharmaceutical companies that are conducting clinical trials are ongoing

Coronavirus, vaccine, covid, drugs, Sepsivac, clinical trials
For instance, if vaccines do not provide long-lasting immunity, a patient may need repeated vaccinations instead of a single dose
Press Trust of India Singapore
2 min read Last Updated : Nov 10 2020 | 9:07 PM IST

Singapore will work towards securing a "portfolio" of COVID-19 vaccines to cater to different segments of the population instead of relying on one vaccine, Health Minister Gan Kim Yong said on Tuesday.

Speaking during a virtual press conference by the multi-ministry task force on COVID-19, Gan said that the application of a vaccine will have to take into account varying efficacy and safety profiles for different groups.

"Some vaccines may be effective for different segments of the population. Some may not be effective for children...and some may not be effective for seniors," The Straits Times quoted Gan as saying.

Gan added that even when vaccines become available, it will have to be given out progressively as it is not possible to vaccinate the entire nation at once.

Negotiations with various pharmaceutical companies that are conducting clinical trials are ongoing, added Gan.

An expert committee on COVID-19 vaccination set up last month will assess the data coming out of the trials and advise the ministry on its vaccination strategy, said the minister.

He said details about which vaccines will make the list and which segments of the population will receive a vaccine are still being worked out.

The Health Ministry's director of medical services, Associate Professor Kenneth Mak, noted that one vaccine candidate developed by the pharmaceutical company Pfizer was recently found to be more than 90 per cent effective.

While this is welcome news, Prof Mak said more information is needed about the Pfizer vaccine and others that are close to finishing phase three trials.

For instance, if vaccines do not provide long-lasting immunity, a patient may need repeated vaccinations instead of a single dose.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus TestsSingapore

First Published: Nov 10 2020 | 9:04 PM IST

Next Story